Skip to main content

Table 4 Immune responses against DTPw-HBV/Hib vaccine antigens 1 month after 3-dose primary vaccination (ATP immunogenicity cohort)

From: Primary vaccination with the 10-valent pneumococcal non-typeable Haemophilus influenzae protein D conjugate vaccine (PHiD-CV) in infants in Mali and Nigeria: a randomized controlled trial

  PHiD-CV group Control group
Antigen (cut-off) N % (95% CI) GMC (95% CI) N % (95% CI) GMC (95% CI)
Diphtheria toxoid (0.1 IU/mL) 110 100 (96.7-100) 4.103 (3.527-4.773) 112 100 (96.8-100) 3.130 (2.731-3.588)
Tetanus toxoid (0.1 IU/mL) 110 100 (96.7-100) 6.484 (5.511-7.628) 112 100 (96.8-100) 4.588 (3.880-5.426)
Bordetella pertussis (15 EL.U/mL) 110 100 (96.7-100) 111.9 (102.0-122.7) 111 100 (96.7-100) 124.9 (111.7-139.7)
HBs (10 mIU/mL) 91 97.8 (92.3-99.7) 1835.1 (1384.0-2433.2) 96 100 (96.2-100) 1485.5 (1198.7-1840.9)
PRP (0.15 μg/mL) 110 100 (96.7-100) 18.461 (14.256-23.907) 112 99.1 (95.1-100) 10.137 (7.515-13.673)
  1. NOTE. GMC, geometric mean antibody concentration; HBs, hepatitis B surface antigen; PRP, Haemophilus influenzae type b polyribosylribitol phosphate; N, number of subjects with available results
Back to article page

BMC Public Health

ISSN: 1471-2458

Contact us

\